Τετάρτη 3 Μαΐου 2017

Absolute benefits of empagliflozin in type 2 diabetes: a game changer?

The modes of action and clinical implications of several of the newest classes of antidiabetic drugs used as monotherapy and as add-on therapy have been extensively reviewed in recent publications.1 2 Sodium-glucose cotransporter 2 (SGLT-2) inhibitors (eg, empagliflozin) belong to one such novel class and act via interference with proximal renal tubular reabsorption of glucose; about 90% of such reabsorption depends on this cotransporter. They therefore reduce blood glucose concentrations, promote weight reduction and lower blood pressure through glycosuria and osmotic diuresis. Moreover, since their activity is independent of insulin, they are efficacious even in the presence of pancreatic beta cell failure, which is in marked contrast to many other antidiabetic drugs. Furthermore, polyuria and polydipsia are uncommon. Gliptins (eg, saxagliptin) form another new class of oral antidiabetic agents that reduce glucagon secretion but promote insulin release by interfering with the degradation of incretins (intestinal hormones...



from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2p7uVLd
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις